Brief: Serina Therapeutics Completes Sentinel Dosing In Cohort 1 Of Phase 1B Registrational Trial Of SER-252
09/07/2026 18:29
BRIEF-Serina Therapeutics Completes Sentinel Dosing In Cohort 1 Of Phase 1B Registrational Trial Of SER-252 July 9 (Reuters) - Serina Therapeutics Inc SER.A:
SERINA THERAPEUTICS ANNOUNCES COMPLETION OF SENTINEL DOSING IN COHORT 1 OF PHASE 1B REGISTRATIONAL TRIAL OF SER-252 FOR ADVANCED PARKINSON’S DISEASE
Source text: ID:nGNX7g2NV2
Further company coverage: SER.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Serina Therapeutics
See all newsBrief: Serina Therapeutics Inc Reports Cohort 1 Observations From Ser-252 Registrational Study In Advanced Parkinson’S Disease And Advances To Cohort 2
Brief: Serina Therapeutics - Offers Up To 12,500,000 Shares Of Common Stock By Roth Principal Investments - SEC Filing
Serina Therapeutics Q2 net loss widens on higher expenses
Brief: Serina Therapeutics Appoints Farrell Simon To Its Board Of Directors
Brief: Serina Therapeutics Completes Sentinel Dosing In Cohort 1 Of Phase 1B Registrational Trial Of SER-252